extrapyramidal side effects


Also found in: Encyclopedia.

extrapyramidal side effects

side effects that mimic extrapyramidal disease and are caused by drugs that block dopamine receptor sites in the extrapyramidal system tract. See also parkinsonism.
References in periodicals archive ?
The attenuation of schedule-induced polydipsia by dopamine blockers is not an expression of extrapyramidal side effect liability.
advantage is that the type of extrapyramidal side effects seen with droperidol tends to be akathisia, 'which is common, but I have never seen a dystonic reaction.
Among the most serious are extrapyramidal side effects (EPS), which include dystonic reactions, akathisia, and parkinsonism.
The study also looked at extrapyramidal side effects for those exposed to trimethobenzamide.
She received haloperidol, a drug primarily cleared through the 2D6 pathway that "also has one of the highest frequencies; of extrapyramidal side effects.
I reasoned that if the newer antipsychotics indeed were less likely to cause acute, parkinsonian or extrapyramidal side effects, then TD would be virtually eradicated.
Adult patients presenting to the emergency department at Monte-fiore Medical Center in New York with acute migraine were randomized to receive one of the three doses of metoclopramide in an IV infusion over 20 minutes coadministered with 25 mg diphenhydramine to prevent the development of extrapyramidal side effects such as akathisia.
In preclinical studies, they do not induce secondary negative symptoms, extrapyramidal side effects (physical symptoms that can occur in individuals taking antipsychotic medications) or neuroendocrine disturbances associated with current agents.
Background & objectives: Use of typical antipsychotics like haloperiflol in treatment of schizophrenia is associated with a high incidence of extrapyramidal side effects.
Coverage includes psychiatric disorders, drugs for ADHD, antidepressants, electroconvulsive treatment, antipsychotics, agents for treating extrapyramidal side effects, sedatives, mood stabilizers, and drugs abused.
Data from preclinical and phase I studies demonstrated that the compound may retain the efficacy of currently available typical and atypical antipsychotic drugs while achieving a much higher safety profile as evidenced by a lack of metabolic or extrapyramidal side effects.
In addition, the combined antagonism at 5-HT2A and partial agonism at D2 receptors in vivo suggests ACP-104 may produce antipsychotic activity with reduced extrapyramidal side effects.

Full browser ?